Premium
Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII
Author(s) -
POON M.C.
Publication year - 2006
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2006.01336.x
Subject(s) - medicine , factor ix , pharmacokinetics , volume of distribution , recombinant dna , clotting factor , coagulation , body weight , factor vii , platelet , immunology , pharmacology , endocrinology , biochemistry , chemistry , gene
Summary. There is now a volume of literature on the pharmacokinetics (PK) of coagulation factor concentrates, although the majority is on factor VIII (FVIII) and factor IX (FIX). PK of FIX and FVIII are different with FIX having a larger volume of distribution ( V dss ), higher elimination clearance (CL), longer mean resident time (MRT) and longer terminal half‐life ( T 1/2, β ). Factor IX in vivo recovery (IVR) is also much shorter possibly due to reversible binding of FIX to the endothelium and possibly to platelets. There is considerable FIX PK variability between products (particularly between plasma‐derived FIX and recombinant FIX), and between individuals. Important inter‐individual factors leading to PK variability include age and body weight because plasma volume as a fraction of body weight decreases with increasing weight and hence age. Thus, IVR increases with body weight and hence age and is consequently lower in children than in adults. Absolute V dss and CL increase linearly with body weight and age in children and adolescents, becoming stable in adults with more stable weight. Inter‐individual variability also likely applies to other clotting factors, particularly to recombinant activated FVII (rFVIIa) but likely also to the less well studied factor XIII (FXIII). The former is known to have an extremely short T 1/2, β , large V dss , high CL, short MRT, whereas the latter has an extremely long T 1/2, β , large V dss , short CL and long MRT. Both are discussed in this article. Understanding of PK of specific clotting factors in individual patients is important in order to make decisions regarding appropriate dosage and dosage intervals to treat patients, and to allow by means of computer modelling the determination of dosage to achieve target trough level at various dosing intervals for patients undergoing prophylaxis.